Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT

View through CrossRef
Objective. Describe and characterize the peculiarities of the chronic myeloid leukemia (CML) course and response to treatment in patients irradiated as a result of the Chornobyl nuclear power plant (ChNPP) accident based on the assessment of clinical-laboratory and clinical parameters. Materials and methods. The CML patients (n = 33) exposed to ionizing radiation as a result of the ChNPP accident were enrolled. The comparison group consisted of CML patients (n = 725) with no history of radiation exposure. All patients were in the chronic phase of the disease. Clinical, hematological and molecular genetic research methods were applied. Results. Patients exposed to ionizing radiation as a result of the ChNPP accident had no differences in CML manifestation, as well as in classical genetic markers at the onset of the disease compared with patients with no history of radiation exposure. Reduction of tumor clone on imatinib therapy was significantly less effective in the patients exposed to ionizing radiation than in cases of no history of radiation exposure. Cases of primary resistance were statistically significantly prevalent in the ChNPP accident consequences clean-up workers while in the residents of radiologically contaminated areas a statistically significant increase in probability of loss of complete cytogenetic response (development of secondary resistance) to imatinib therapy was found. An association was found between the radiation exposure and probability of loss of complete cytogenetic response to imatinib therapy in this group of patients. Conclusion. The radiation exposure in the history even many years before the onset of CML is an unfavorable exogenous factor responsible for the development of resistance to imatinib therapy. Key words: chronic myeloid leukemia, ionizing radiation, tyrosine kinase inhibitors, response to treatment.
Title: CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT
Description:
Objective.
Describe and characterize the peculiarities of the chronic myeloid leukemia (CML) course and response to treatment in patients irradiated as a result of the Chornobyl nuclear power plant (ChNPP) accident based on the assessment of clinical-laboratory and clinical parameters.
Materials and methods.
The CML patients (n = 33) exposed to ionizing radiation as a result of the ChNPP accident were enrolled.
The comparison group consisted of CML patients (n = 725) with no history of radiation exposure.
All patients were in the chronic phase of the disease.
Clinical, hematological and molecular genetic research methods were applied.
Results.
Patients exposed to ionizing radiation as a result of the ChNPP accident had no differences in CML manifestation, as well as in classical genetic markers at the onset of the disease compared with patients with no history of radiation exposure.
Reduction of tumor clone on imatinib therapy was significantly less effective in the patients exposed to ionizing radiation than in cases of no history of radiation exposure.
Cases of primary resistance were statistically significantly prevalent in the ChNPP accident consequences clean-up workers while in the residents of radiologically contaminated areas a statistically significant increase in probability of loss of complete cytogenetic response (development of secondary resistance) to imatinib therapy was found.
An association was found between the radiation exposure and probability of loss of complete cytogenetic response to imatinib therapy in this group of patients.
Conclusion.
The radiation exposure in the history even many years before the onset of CML is an unfavorable exogenous factor responsible for the development of resistance to imatinib therapy.
Key words: chronic myeloid leukemia, ionizing radiation, tyrosine kinase inhibitors, response to treatment.

Related Results

Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract Abstract 1606 Introduction: Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical...
Chronic Myeloid Leukemia Following Exposure to Radioactive Iodine (I 131): A Systematic Review
Chronic Myeloid Leukemia Following Exposure to Radioactive Iodine (I 131): A Systematic Review
Abstract Introduction Therapy-related leukemia or secondary leukemia are the terms that describe the occurrence of leukemias following exposure to hem...
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract Background: Chemotherapy and radiotherapy are effective cancer treatment options but they are accompanied by serious side effects. Therefore, more effective...
EphB4 Expression and Biological Significance in Drug Resistance of Myeloid Leukemia
EphB4 Expression and Biological Significance in Drug Resistance of Myeloid Leukemia
Abstract Abstract 4725 Chemotherapy is widely used in treatment of myeloid leukemia, the efficancy of which, however, is often hampered by the develop...

Back to Top